Blood test may predict chemo success in colorectal cancer

NCT ID NCT01596790

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a new blood test called EPISPOT can predict how well chemotherapy works in people with metastatic colorectal cancer. Researchers measured circulating tumor cells in 168 patients before and during treatment. The goal was to see if early changes in these cells could help doctors personalize therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this blood test could help doctors choose the best first-line treatment for metastatic colorectal cancer patients.

What could go wrong

This is an observational study, not a treatment trial. The test may not prove reliable enough to change clinical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm Neoplastic Cells, Circulating

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medical Oncology, CHU St Eloi

    Montpellier, 34090, France